Gapping up
News:
- LUNR +54.3% (wins NASA contract worth up to $4.82 bln)
- APLT +40.9% (provides regulatory update on govorestat for the treatment of Classic Galactosemia)
- IAUX +9.3% (names Richard Young as CEO)
- AIOT +6% (acquires Fleet Complete)
- IMUX +3.7% (Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis)
- BAK +2.9% (provides news clarifications)
- TGTX +2.8% (reports new data for BRIUMVI (ublituximab-xiiy) demonstrated that 92% of patients with relapsing multiple sclerosis were free from disability progression after 5 years of treatment)
- EWTX +2.6% (to discuss top-line data from Phase 1 and Phase 2 trials)
- CMPO +2.5% (Resolute completes acquisition of majority interest)
- ROIV +2.5% (Organon to acquire Dermavant from Roviant)
- QTRX +2.2% (Director bought 47000 shares)
- MNKD +2% (received clearance from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) to initiate the Phase 3 study (ICoN-1) of Clofazimine Inhalation Suspension for the treatment of NTM lung disease)
- GLNG +1.7% (signs EPC agreement with CIMC Raffles)
- DNA +1.3% (announces the launch of Ginkgo Datapoints to usher in the next era of biotechnology by making the training of AI models easier and more efficient)
- CRM +1.2% (CRM and NVDA to collaborate to develop AI capabilities for the enterprise)
- BJ +1.1% (Director bought 2455 shares)
- PPBT +1.1% (reported new positive biomarker findings for its lead oncology therapeutic candidate CM24)